CheckMate 066 included patients treated with nivolumab versus dacarbazine and showed that nivolumab improves OS in previously untreated melanoma patients and showed that given the magnitude of clinical benefit observed in patients who got nivolumab, PD-L1 status alone is not helpful in the selection of patients for nivo treatment (26). Here, CD274 is linked to melanoma.